Stephen Timms, MD
Neurology · Wheeling, WVNPI 1922009380
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $3,105 of the $3,544 with a category attached, or 87.6%. It is spread thinly across 29 manufacturers, the largest accounting for just 19.7% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $1,943 and has fallen 95.2% since, to $93 in 2025.
Across 188 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- UCB, Inc.$699
- Teva Pharmaceuticals USA, Inc.$495
- Biogen$313
- Lilly USA, LLC$249
- Novartis$220
- AstraZeneca$159
- plus $1K from 23 others
What the payments were for
- Speaking & faculty fees$411%
- Food & beverage$3,10588%
- Education$39711%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| UCB, Inc. | 46 | $699 |
| Teva Pharmaceuticals USA, Inc. | 15 | $495 |
| Biogen | 14 | $313 |
| Lilly USA, LLC | 14 | $249 |
| Novartis | 17 | $220 |
| AstraZeneca | 10 | $159 |
| Amgen(2 entities) | 8 | $149 |
| Sanofi | 6 | $149 |
| AbbVie | 3 | $126 |
| Sunovion Pharmaceuticals Inc. | 8 | $105 |
| Livanova USA, Inc. | 1 | $97 |
| Argenx US, Inc. | 4 | $89 |
| Acadia Pharmaceuticals Inc | 5 | $82 |
| EMD Serono, Inc. | 4 | $67 |
| Jazz Pharmaceuticals Inc. | 2 | $63 |
| Sumitomo Pharma America, Inc. | 5 | $61 |
| Amneal Pharmaceuticals LLC | 4 | $55 |
| Lundbeck LLC | 3 | $54 |
| Tanabe Pharma America, Inc. | 2 | $45 |
| MDD US Operations, LLC | 3 | $42 |
| Acorda Therapeutics, Inc | 3 | $41 |
| Avanir Pharmaceuticals, Inc. | 2 | $37 |
| Neurelis, Inc. | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 2 | $26 |
| Pfizer | 1 | $24 |
| CSL Behring | 1 | $20 |
| Abbott | 1 | $18 |
| SK Life Science, Inc. | 1 | $16 |
| Genentech USA, Inc. | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$115
How this compares
$3,544 in reported general payments places this provider in the 70th percentile of 93 neurology providers in West Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| PanzygaImmun Glob G(Igg)-Ifas/Glycine | 26 | $499,552 |
| NuplazidPimavanserin Tartrate | 44 | $269,068 |
| Avonex (4 Pack)Interferon Beta-1a | 11 | $90,924 |
| Nurtec OdtRimegepant Sulfate | 33 | $71,267 |
| Dimethyl Fumarate | 16 | $67,203 |
| Aimovig AutoinjectorErenumab-Aooe | 46 | $41,371 |
| GlatopaGlatiramer Acetate | 12 | $29,621 |
| VimpatLacosamide | 21 | $25,167 |
| Tiagabine Hcl | 13 | $18,553 |
| NamzaricMemantine Hcl/Donepezil Hcl | 32 | $18,137 |
| UbrelvyUbrogepant | 12 | $12,525 |
| Lacosamide | 161 | $12,377 |
| Gabapentin | 739 | $11,258 |
| Carbamazepine ErCarbamazepine | 104 | $11,139 |
| Levetiracetam | 433 | $9,654 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerPanzyga, Nurtec Odt, Dilantin | $24 | $574,95683 claims |
| Acadia Pharmaceuticals IncNuplazid | $82 | $269,06844 claims |
| BiogenAvonex (4 Pack) | $313 | $90,92411 claims |
| AbbVieNamzaric, Ubrelvy | $126 | $30,66244 claims |
| UCB, Inc.Vimpat | $699 | $25,16721 claims |
| Amneal Pharmaceuticals LLCPyridostigmine Bromide | $55 | $4,36158 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 93 neurology providers in West Virginia.
Other neurology in Wheeling
- Rebecca BarnesWheeling$3K
- Brenda AdamovichWheeling$2K
- John TellersWheeling$583
- Barry VaughtCrab Orchard$1.4M
- Paul FergusonHuntington$649K
- Umer NajibMorgantown$246K
- Muhammed Nasher-AlneamCharleston$73K
- Robert LewisHurricane$73K
- Lauren SeebergerCharleston$72K
- Cheryl SmithMorgantown$68K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.